SCHEMBL7910239

SCHEMBL7910239

Cc1nc(-c2ccc(C(=O)N3CCC(C(=O)N[C@@H](C)c4ccc(F)cc4)(c4ccc(F)cn4)CC3)cc2)no1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 3/20 0.39
GRM5 P41594 1/20 0.39
CLPP Q16740 1/20 0.39
MGLL Q99685 1/20 0.38
KIT P10721 1/20 0.38
STAT3 P40763 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HDAC4 P56524 4/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PLK1 P53350 1/20 0.36
GABRA5 P31644 1/20 0.36
LMNA P02545 1/20 0.36
AADAT Q8N5Z0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092395 0.89 TACR3 (0.42) TACR3GRM5CLPPMGLLKIT
SCHEMBL7909251 0.89 KIT (0.44) KITMEN1KMT2AALDH1A1LMNA
SCHEMBL7910840 0.88 TACR3 (0.38) TACR3GRM5KITSTAT3GABRA5
SCHEMBL13092247 0.87 MGLL (0.44) TACR3GRM5CLPPMGLLMEN1
SCHEMBL3109100 0.85 MGLL (0.45) TACR3GRM5CLPPMGLLSTAT3
SCHEMBL7909981 0.82 GRM5 (0.42) TACR3GRM5CLPPMGLLKIT
SCHEMBL13092275 0.82 GRM5 (0.45) TACR3GRM5CLPPMGLLKIT
SCHEMBL13092382 0.81 TACR3 (0.41) TACR3GRM5CLPPMGLLMEN1
SCHEMBL3097369 0.81 TACR3 (0.41) TACR3GRM5CLPPMGLLSTAT3
SCHEMBL7908887 0.81 GRM5 (0.45) TACR3GRM5CLPPMGLLKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TACR3 41/4885GRM5 289/4885CLPP 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.